IL155273A0 - Pharmaceutical compositions comprising an aplidine compound - Google Patents

Pharmaceutical compositions comprising an aplidine compound

Info

Publication number
IL155273A0
IL155273A0 IL15527301A IL15527301A IL155273A0 IL 155273 A0 IL155273 A0 IL 155273A0 IL 15527301 A IL15527301 A IL 15527301A IL 15527301 A IL15527301 A IL 15527301A IL 155273 A0 IL155273 A0 IL 155273A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
aplidine
aplidine compound
compound
carnitine
Prior art date
Application number
IL15527301A
Other languages
English (en)
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0025044A external-priority patent/GB0025044D0/en
Priority claimed from GB0025209A external-priority patent/GB0025209D0/en
Priority claimed from PCT/GB2000/004349 external-priority patent/WO2001035974A2/en
Priority claimed from GB0107373A external-priority patent/GB0107373D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Priority claimed from PCT/GB2001/004555 external-priority patent/WO2002030441A2/en
Publication of IL155273A0 publication Critical patent/IL155273A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
IL15527301A 2000-10-12 2001-10-12 Pharmaceutical compositions comprising an aplidine compound IL155273A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0025044A GB0025044D0 (en) 2000-10-12 2000-10-12 Toxicity protection
GB0025209A GB0025209D0 (en) 2000-10-13 2000-10-13 Treatment of cancers
PCT/GB2000/004349 WO2001035974A2 (en) 1999-11-15 2000-11-15 Aplidine treatment of cancers
GB0107373A GB0107373D0 (en) 2001-03-23 2001-03-23 Aplidine
PCT/GB2001/004555 WO2002030441A2 (en) 2000-10-12 2001-10-12 Treatment of cancers by aplidine in conjunction with a myoprotector

Publications (1)

Publication Number Publication Date
IL155273A0 true IL155273A0 (en) 2003-11-23

Family

ID=27255931

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15527301A IL155273A0 (en) 2000-10-12 2001-10-12 Pharmaceutical compositions comprising an aplidine compound

Country Status (14)

Country Link
US (1) US7507766B2 (es)
JP (1) JP2010031043A (es)
KR (1) KR20030038812A (es)
CN (1) CN1479622A (es)
AT (1) ATE299028T1 (es)
BR (1) BR0114604A (es)
CZ (1) CZ2003993A3 (es)
ES (1) ES2243555T3 (es)
HK (1) HK1054191A1 (es)
IL (1) IL155273A0 (es)
NO (1) NO20031673L (es)
NZ (1) NZ525196A (es)
PL (1) PL361179A1 (es)
RU (1) RU2003113210A (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2261104C2 (ru) * 1999-11-15 2005-09-27 Фарма Мар С.А. Лечение злокачественных опухолей аплидином
WO2004080421A2 (en) * 2003-03-12 2004-09-23 Pharma Mar, S.A. Improved antitumoral treatments
WO2007100385A2 (en) * 2005-10-31 2007-09-07 Genentech, Inc. Macrocyclic depsipeptide antibody-drug conjugates and methods
PL2029155T3 (pl) * 2006-02-28 2016-09-30 Ulepszony sposób leczenia szpiczaka mnogiego
EP2205263A1 (en) * 2007-10-19 2010-07-14 Pharma Mar, S.A. Improved antitumoral treatments
CN101965191A (zh) * 2008-03-07 2011-02-02 法马马有限公司 改善的抗癌治疗
CA2838387A1 (en) 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
DE3161556D1 (en) 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US5861439A (en) 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
DE69703294T2 (de) 1996-05-22 2001-05-17 Protarga Inc Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
DE69708116T2 (de) 1996-07-03 2002-07-04 Paxton C G Ltd Behälter
ATE245435T1 (de) 1996-10-24 2003-08-15 Univ Illinois Totalsynthese des amino hip analogen von didemnin a
ATE321773T1 (de) 1996-10-24 2006-04-15 Univ Illinois Semisynthetisches verfahren zur herstellung von didemninanalogen
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
CA2288639A1 (en) 1997-05-07 1998-11-12 Pharma Mar, S.A. Aplidine as an l-type calcium channel enhancer
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
PT1100589E (pt) 1998-07-30 2005-05-31 Sigma Tau Ind Farmaceuti Utilizacao de propionil-l-carnitina e acetil-l-carnitina na preparacao de medicamentos com actividade anticancerigena
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
AU781897B2 (en) 1999-05-25 2005-06-23 Point Therapeutics, Inc. Anti-tumor comprising boroproline compounds
RU2261104C2 (ru) 1999-11-15 2005-09-27 Фарма Мар С.А. Лечение злокачественных опухолей аплидином
DK1276491T3 (da) 2000-04-07 2007-02-05 Univ Pennsylvania Tamandarin- og didemnin-analoger og fremgangsmåder til fremstilling og anvendelse af dem
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
AU2002213053B2 (en) 2000-10-05 2006-12-21 Immunex Corporation Nectin polypeptides, polynucleotides, methods of making and use thereof
HUP0302293A3 (en) 2000-10-12 2006-04-28 Pharma Mar Sa Treatment of cancers by aplidine in conjunction with a myoprotector
WO2002032374A2 (en) 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
EP1435991B1 (en) 2001-10-19 2008-10-15 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
WO2004080421A2 (en) 2003-03-12 2004-09-23 Pharma Mar, S.A. Improved antitumoral treatments

Also Published As

Publication number Publication date
BR0114604A (pt) 2003-10-14
NO20031673L (no) 2003-06-12
HK1054191A1 (zh) 2003-11-21
US20040010043A1 (en) 2004-01-15
RU2003113210A (ru) 2004-11-27
NZ525196A (en) 2004-09-24
US7507766B2 (en) 2009-03-24
CZ2003993A3 (cs) 2004-02-18
KR20030038812A (ko) 2003-05-16
CN1479622A (zh) 2004-03-03
JP2010031043A (ja) 2010-02-12
NO20031673D0 (no) 2003-04-11
ES2243555T3 (es) 2005-12-01
PL361179A1 (en) 2004-09-20
ATE299028T1 (de) 2005-07-15

Similar Documents

Publication Publication Date Title
HUP0200503A3 (en) N-cyanomethyl amides as protease inhibitors and pharmaceutical compositions containing them
MXPA04008772A (es) Composiciones de clorhidrato de naltrexona.
MY129406A (en) Taste masked liquid pharmaceutical compositions
MY129356A (en) Electrospun pharmaceutical compositions
HUP0301405A3 (en) Compositions containing therapeutically active components having enhanced solubility
HUP0103464A3 (en) Prodrugs of proton pump inhibitors and pharmaceutical compositions containing them
DK1157037T3 (da) GCSF-konjugater
AP1450A (en) Solid oral dosage form comprising a combination of metformin and glibenclamide.
MY134190A (en) Compositions and methods for stimulating gastrointestinal motility.
HK1070305A1 (en) Pharmaceutical composition comprising gabapentin or an analogue thereof and an sg(a)-aminoamide and its analgesic use
YU75701A (sh) Farmaceutski preparat
ID27503A (id) Tts yang mengandung antioksidan
HUP0302922A3 (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation and pharmaceutical compositions containing them
HUP0104934A3 (en) Peptide analogues of pacap, pharmaceutical compositions comprising thereof and their use
HK1028568A1 (en) Alpha-ketoamide multicatalytic protease inhibitors
HUP0301240A3 (en) Pyridazine compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors and pharmaceutical compositions containing them
HUP0600241A2 (en) Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same
SI1121127T1 (en) Oral pharmaceutical compositions containing buprenorphin
HUP0400494A3 (en) Polyamine analogues as cytotoxic agents and pharmaceutical compositions containing them
IL155273A0 (en) Pharmaceutical compositions comprising an aplidine compound
HUP0303636A3 (en) Dihydronaphthalenederivative compounds and pharmaceutical compositions containing them as active ingredient
WO2002030441A3 (en) Treatment of cancers by aplidine in conjunction with a myoprotector
WO2002026324A3 (en) Tocol-based compositions containing amiodarone
EP1117681A4 (en) NEW PEPTIDES
MXPA04006269A (es) Composicion farmaceutica que comprende un inhibidor de alfa-glucosidasa y acido 4-oxobutanoico y uso de la misma para tratamiento de diabetes.